Khiron Life Sciences Inc (CVE:KHRN) OTCMKTS:KHRNF) momentum kept rolling Monday, as the predominantly LATAM operator closed at a new all-time daily high. This was the fourth consecutive such close for Khiron—on heavy volume to boot. We chronicle Khiron’s impressive recent run to the top.
[stock_chart symbol=”KHRN:TSV” width=”60%”]
In a sense, Khiron Life Sciences shouldn’t even be undergoing this bullish impulse to begin with. The company has not released a presser since September 12th; or material presser since August 23rd. Even then, the news provoked a short-term smothering effect on price: KHRN announced a common share offering at $0.90/share to raise aggregate gross proceeds of up to $11,250,000—a 10% discount to market. The junior market—save for Aleafia Health Inc.—has mostly consolidated over the past week. For outsiders trying to understand this move, the catalyst may not seem apparent.
But for those in the know, the move in Khiron Life Sciences is more about execution and scarcity than it is about glitzy press releases. It’s about an impressive management team which includes former DEA Supervisor Matt Murphy, CEO Alvaro Torres (SNC-Lavalin Colombia) and former Mexican president Vincente Fox. It’s about their pure-play LATAM operations, which are likely coveted by several larger LPs wishing to enter the continent expeditiously. And now, it’s about sentiment as a major Canadian investment bank affirmed what we suspected all along.
Canaccord Genuity provided the kerosene to already-bullish price action by initiating coverage on KHRN with a “speculative buy” rating and $3.00 price target on September 20th. The reasons cited are similar to the ones the Midas Letter has touted since May: superior management, rare pure-play LATAM exposure, and growing medical client base.
But another common theme becomes apparent as I further parse through Canaccord’s research report: valuation. This fact is strewn throughout, mimicking the narrative we’ve been reciting in top line terms all along. Comparatively speaking, Khiron is downright cheap compared to its peers. The money quote encapsulating this truism can be found on page 37, when Canaccord says the following:
We believe the company trades at a significant discount to the Canadian and US peer group, with an EV to 2020E EBITDA of 3.2x, which reflects an ~80% discount to the Canadian average of 16.5x.
Yes, eighty percent.
Backing up this conclusion, Canaccord notes that KHRN trades at a valuation discount compared to recent peer LATAM transactions. The average value afforded to four Colombian acquired operators so far: $246 million. This includes the $290 million Aurora Cannabis Inc. paid for ICC Labs Inc. earlier this month. Fully diluted, KHRN is only valued at around $156 million, despite the fact their clinic distribution model is much more advanced.
Khiron Life Sciences CEO Alvaro Torres discusses securing multiple medical cannabis endorsements from the two largest medical associations in Colombia
This distinction matters because the importance of ultra-efficient production capacity is not as prized in a country like Columbia, where labor is cheap, arable land is pennies on the dollar, and industrial-scale growing is conducted outdoors. Khiron business structure is geared towards nurturing a medical client portfolio, not large scale cannabis production. Instead of playing that skinny margin game, the company has made a purposeful decision to pursue higher margins the current model provides. According to Cannacord, this will equate to a gross margins reaching the mid-forties in percentage terms by 2021E.
In terms of the rally itself, prices came within a penny of touching $2.00/share, finishing up $0.13 to $1.82/share (↑7.69%) on Day 3 of the run. Volume was brisk, chiming-in at 2.12 million shares—the stock’s second highest total aside from its inaugural, May 24th session. Shares have almost doubled in less than a month, and the company is becoming a household name among the cannabis investors.
Whether Khiron Life Sciences can continue to run remains to be seen. But keep in mind there are only around 64 million shares outstanding—among the lowest fully-diluted share structure of any prominent operator in the sector. With relative strength technicals such as the 20-period RSI (daily) nowhere near overbought territory, and with the company trading in blue sky territory, there’s room for upside extension. The recent move in Aleafia—a Canadian operator executing a similar clinic distribution model domestically—demonstrates that blue sky breakouts can run longer than initially imagined (although ALEF has incurred multiple catalysts along the way).
We await to see whether Khiron can maneuver a similar feat in lieu of material news flow, should recent trends continue.
**IMPORTANT! BY VIEWING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
Notice for Forward-Looking Information
Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that Khiron Life Sciences Corp will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and KHIRON’s sales along with it; KHIRON’s intended acquisition of various foreign companies and expansion into the European and South and North American markets; that cosmeceuticals is and will continue to be a fast growing and profitable sector of the cannabis industry; and that it will be able to carry out its business plans.
Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on KHIRON. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets KHIRON operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; KHIRON not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; KHIRON’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; KHIRON’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal and foreign laws; and other regulatory risks relating to KHIRON’s business, financings and strategic acquisitions, including securities laws, trade rules, and foreign country regulation that is not the same as Canadian or US regulations.
PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. James West, Global Financial Network Ltd. and Midas Letter Media Corp. and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by KHIRON $100,000 per month for one year as of May 15, 2019 for a newsletter campaign and certain banner ads, of which a portion is spent to produce multi-media content and a portion to the advertising budget targeting investor. In addition, the Company owns 150,000 Restricted Share Units (RSU’s) of KHIRON, and will benefit from its price appreciation. This compensation and our rights ownership in KHIRON is a major conflict with our ability to be unbiased, more specifically:
This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by KHIRON to conduct investor awareness advertising and marketing for KHIRON. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the profiled company. The profiled company or its affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our newsletters experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.
SHARE OWNERSHIP. The Company, which includes the owner and publisher of the Midas Letter owns Restricted Share Units of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Company will not notify the market when it decides to buy or sell shares of this profiled company in the market. The Company may be buying and selling additional shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
NOT AN INVESTMENT ADVISOR. The Company and its affiliates are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.